Pharmaceuticals, Q3 and Recursion
Digest more
Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive Phase 2 data for oral MEK1/2 inhibitor REC-4881 in familial adenomatous polyposis. The biotech plans to start a registrational trial of REC-4881,
Zacks Investment Research on MSN
Recursion's Q3 earnings beat estimates on Sanofi milestone revenues
Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the third quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 24 cents. The company had incurred a loss of 36 cents per share in the year-ago quarter.
Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.
Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair, effective October 31,
Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced the pricing of an underwritten offering of 61,
Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous polyposis (FAP) therapy generated positive mid-stage clinical data.
The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve the new-drug discovery process with artificial intelligence.
10d
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Webinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on Tuesday, November 3,
Key TakeawaysAbsci fell 8% today as AI drug discovery peers Schrödinger and Recursion slid in a Nasdaq sell-off. These stocks trade together on sentiment, so the drop says little about Absci’s business.
